Marshall Wace LLP Raises Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Marshall Wace LLP boosted its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 19.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 971,143 shares of the company's stock after acquiring an additional 159,791 shares during the quarter. Marshall Wace LLP owned about 2.09% of Pacira BioSciences worth $27,784,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in PCRX. ICA Group Wealth Management LLC purchased a new position in shares of Pacira BioSciences in the 4th quarter worth approximately $30,000. GAMMA Investing LLC increased its position in Pacira BioSciences by 229.6% during the 2nd quarter. GAMMA Investing LLC now owns 1,338 shares of the company's stock valued at $38,000 after buying an additional 932 shares in the last quarter. Park Place Capital Corp purchased a new stake in Pacira BioSciences in the second quarter valued at about $46,000. Innealta Capital LLC acquired a new stake in Pacira BioSciences in the second quarter worth about $50,000. Finally, nVerses Capital LLC lifted its stake in shares of Pacira BioSciences by 800.0% during the second quarter. nVerses Capital LLC now owns 1,800 shares of the company's stock worth $51,000 after buying an additional 1,600 shares during the period. 99.73% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Pacira BioSciences

In other news, CEO Frank D. Lee bought 8,264 shares of the company's stock in a transaction on Monday, August 12th. The stock was bought at an average cost of $12.10 per share, with a total value of $99,994.40. Following the transaction, the chief executive officer now directly owns 107,784 shares in the company, valued at approximately $1,304,186.40. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Pacira BioSciences news, CEO Frank D. Lee bought 8,264 shares of Pacira BioSciences stock in a transaction on Monday, August 12th. The shares were bought at an average cost of $12.10 per share, for a total transaction of $99,994.40. Following the acquisition, the chief executive officer now directly owns 107,784 shares in the company, valued at $1,304,186.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jonathan Slonin sold 2,836 shares of the firm's stock in a transaction that occurred on Tuesday, July 2nd. The shares were sold at an average price of $28.25, for a total transaction of $80,117.00. Following the completion of the transaction, the insider now directly owns 95,557 shares of the company's stock, valued at approximately $2,699,485.25. The disclosure for this sale can be found here. Over the last ninety days, insiders bought 11,176 shares of company stock worth $136,240 and sold 4,281 shares worth $105,494. Company insiders own 6.40% of the company's stock.

Pacira BioSciences Trading Up 1.5 %

PCRX traded up $0.21 on Friday, hitting $14.54. The company had a trading volume of 632,728 shares, compared to its average volume of 906,491. The company's fifty day moving average price is $15.94 and its 200 day moving average price is $23.58. Pacira BioSciences, Inc. has a 1 year low of $11.16 and a 1 year high of $35.95. The company has a current ratio of 6.82, a quick ratio of 5.70 and a debt-to-equity ratio of 0.67. The firm has a market cap of $676.78 million, a P/E ratio of 10.24 and a beta of 0.84.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last released its quarterly earnings results on Tuesday, July 30th. The company reported $0.64 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.53 by $0.11. Pacira BioSciences had a net margin of 9.21% and a return on equity of 13.22%. The business had revenue of $178.02 million for the quarter, compared to the consensus estimate of $173.31 million. As a group, equities analysts expect that Pacira BioSciences, Inc. will post 2.24 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on PCRX shares. HC Wainwright cut their price target on shares of Pacira BioSciences from $57.00 to $39.00 and set a "buy" rating on the stock in a report on Monday, August 12th. Barclays cut Pacira BioSciences from an "overweight" rating to an "equal weight" rating and cut their price objective for the company from $38.00 to $25.00 in a research report on Wednesday, July 3rd. Needham & Company LLC reduced their price target on shares of Pacira BioSciences from $43.00 to $22.00 and set a "buy" rating for the company in a research report on Monday, August 12th. Piper Sandler cut Pacira BioSciences from an "overweight" rating to a "neutral" rating and lowered their price objective for the stock from $42.00 to $11.00 in a report on Monday, August 12th. Finally, JPMorgan Chase & Co. reiterated an "underweight" rating and set a $10.00 price target (down from $45.00) on shares of Pacira BioSciences in a research report on Monday, August 12th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $24.10.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.